The Longevity Reality Radar
46 approaches, rated by evidence.

Lecanemab and donanemab

Anti-amyloid antibodies (Lecanemab / Donanemab). Brain & neurodegeneration. Reviewed Jul 2026.

Slows cognitive decline by about 27 to 35% in early Alzheimer's, which is not a cure, and brain swelling or bleeding is a real risk.

Stage
Approved
Rung: Available now. Approved or established. Usable today, with a clinician.
Evidence grade
A
outcome RCTs
Randomised outcome data in people. How grades work.

What it is

Monoclonal antibodies that clear amyloid plaques from the brain in early-stage Alzheimer's.

The evidence

Slow cognitive decline by 27–35% in early-stage patients. Not a cure, and carry brain-swelling/bleeding risks (ARIA).

What you can do today

This is available today. Whether it suits you depends on your health, your other medicines and your risks, so discuss it with a clinician who knows your history before starting or changing anything.

Sources

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Brain & neurodegeneration

All 5 in Brain & neurodegeneration.

  • 40 Hz light and sound for Alzheimer'sGrade C, small human trial. Phase 3, no results yet.Strong mouse data and one small human feasibility trial, but the Phase 3 has not reported and human efficacy is not established.
  • GLP-1 drugs for brain healthGrade C, emerging data. Phase 2/3.Early signals of better memory, but large trials are still running and no brain benefit is proven.
  • Stem-cell therapy for Parkinson'sGrade C, small cohorts. Phase 1/2, conditional approval in Japan.Motor symptoms eased or stabilised for up to two years in small cohorts, with no large randomised results yet.
  • Psilocybin for brain agingGrade D, one case report. Speculative.A single Alzheimer's case report and preliminary lab data, not a basis for treating brain aging.